Biofil chemicals and Pharmaceuticals Limited has published its unaudited financial results for the quarter and nine months ended December 31, 2025, in compliance with SEBI regulations. The company made the announcement through newspaper publications on February 14, 2026.

Regulatory Compliance and Publication Details

The financial results were published in accordance with Regulation 47 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The company ensured wide accessibility by publishing the results in both English and Hindi newspapers.

Company Information and Accessibility

Biofil Chemicals and Pharmaceuticals Limited operates with CIN L24233MP1985PLC002709 and maintains its registered office at B/12-B, Industrial Estate, Pologround, Indore-452015 (M.P.). The company has made the complete financial results accessible through multiple channels to ensure transparency.

The newspaper publications include Quick Response Code and webpage information, allowing stakeholders to access comprehensive financial data. The complete results are also available on the company's official website at www.biofilgroup.net .

Corporate Governance and Documentation

Company Secretary and Compliance Officer Apoorv Jain (M. No. A71739) signed the regulatory submission, ensuring proper documentation and compliance procedures. The submission was digitally signed on February 14, 2026, at 12:48:18 +05'30', demonstrating the company's commitment to modern corporate governance practices.

The financial results cover both quarterly performance and nine-month cumulative data, providing stakeholders with comprehensive insights into the company's financial position for the specified period ending December 31, 2025.

Source:

Biofil Chemicals and Pharmaceuticals Limited , a company listed on the Bombay Stock Exchange (BSE), has paid a fine of Rs 4,24,823.60 to BSE Limited under protest. The fine was imposed due to alleged non-compliance with Regulation 17(1)(c) of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements (LODR) Regulations.

Fine Details and Company's Response

The fine imposed by BSE was broken down as follows:

The company had previously filed waiver applications with both the National Stock Exchange (NSE) and BSE. Despite these applications, BSE proceeded with the fines. Biofil Chemicals and Pharmaceuticals made the payment on December 02, while maintaining its stance of protest against the imposed penalties.

Impact on Company Operations

In its disclosure, the company stated that there is no material impact on its financial or operational activities due to this fine. This assertion is supported by the company's recent balance sheet data, which shows growth in various financial metrics.

Financial Position

A look at the company's balance sheet reveals:

Note: All financial figures are in crore rupees

The company's financial position appears to be stable, with growth in both assets and equity over the past year. This supports the company's statement that the fine does not materially impact its financial standing.

Compliance and Regulatory Environment

This incident highlights the strict regulatory environment in which listed companies operate in India. It underscores the importance of adhering to SEBI's LODR regulations, particularly Regulation 17(1)(c), which likely pertains to board composition or related governance matters.

While Biofil Chemicals and Pharmaceuticals has paid the fine, its decision to do so under protest suggests that the company may continue to seek relief or clarification on the alleged non-compliance. This situation serves as a reminder for all listed entities to maintain vigilance in their regulatory compliance efforts.

As the company moves forward, stakeholders will likely be watching closely to see if there are any further developments regarding this regulatory issue and how it might affect the company's governance practices in the future.